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Melanoma cells acquire multiple genetic and epigenetic alterations that promote their metastasis and resis-
tance to available therapies. In this issue of Cancer Cell, Soengas and colleagues reveal that the induction of
endosome-mediated autophagy results in efficient melanoma cell death, thereby offering new potential
means for treatment of this devastating cancer.Advanced melanoma often presents itself
as a metastatic disease highly resistant to
available therapies. Advances made over
the past decades have revealed the
genetic landscape of melanoma forma-
tion, including mutations in NRAS, BRAF,
and related signaling pathways. Often,
resistance of melanoma to chemotherapy
is attributed to modification of cell-death
programs (Ivanov et al., 2003). The work
of Soengas andcolleagues reveals a novel
approach that wemay be able to exploit to
eliminate this devastating cancer (Tormo
et al., 2009). The study describes the
induction of autodigestion of melanoma
cells in culture and in mouse melanoma
models by a dsRNA mimic combined
with a specific delivery vehicle polyethyle-
neimine (PEI). This is a meal we all will
cherish.
Autodigestion of melanoma cells may
sound like science fiction; nonetheless, it
appears to utilize a well-conserved, self-
eating pathway through which cellular
components are eliminated under stress
conditions. This process, known as au-
tophagy, serves to recycle macromole-
cules and organelles to maintain cellular
homeostasis. Autophagy has a cytopro-
tective function by protecting cells from
potentially lethal, stressful conditions,
including metabolic stress and infection.
Recently, we have come to recognize
that dysregulation of autophagy is closely
associated with neurodegenerative and
infectiousdiseases, aswell ascancer (Lev-
ine and Kroemer, 2008). Correspondingly,
growing evidence supports a role for au-
tophagy in cancerpathophysiology (Eisen-
berg-Lerner and Kimchi, 2009). Extensive
crosstalk exists between autophagy and
cell death (Maiuri et al., 2007), although
the factors that govern this crosstalk
remain elusive. The present work demon-
strates that changes in the link betweenthese processes in melanoma can be
exploited to convert cytoprotection to cy-
tokilling. Accordingly, manipulating auto-
phagy may offer a useful approach to
cancer treatment. Along these lines is the
example of renal cell carcinoma, where
small molecules regulating autophagy/
cell death offer a novel treatment opportu-
nity (Turcotte et al., 2008).
In a search for agents that induce
autophagy accompanied by melanoma
tumor cell death, Tormo and colleagues
showed that [pIC] (poly(dI:dC)), a classical
dsRNA mimic, could elicit powerful but
selective induction ofmelanoma cell death
when combined with the carrier PEI
[pIC]PEI. The authors use a combination of
various approaches to dissect the mecha-
nism of action of [pIC]PEI and demonstrate
that [pIC]PEI-mediated death occurs by an
active endosome-autophagosome-lyso-
some fusion, namely endosome-mediated
autophagy. Accordingly, mouse embryo
fibroblasts lacking a key gene required
for autophagy, Atg5, showed a marked
decrease in [pIC]PEI-induced autophagy
and cell death. While melanoma cells
have been extensively studied for changes
in classical apoptotic programs, themech-
anisms underlying their basal and drug-
inducedautophagyare largelyunexplored.
Therefore, the finding that it is possible to
induce melanoma cells’ death by inducing
autophagy is novel and somewhat sur-
prising. Furthermore, given the notion that
tumor cells adapt to high nutritional stress
(Levine and Kroemer, 2008), the treatment
identified by Tormo et al. could bypass
multiple barriers. The authors suggest
that the ability of [pIC]PEI to trigger multiple
fusion cycles is a key for converting cyto-
protective autophagy to one that triggers
efficient death of melanoma cells.
Mechanistically, this study identified
melanoma-differentiation-associated geneCancer Ce5 (MDA-5) as a key component required
to link autophagy to melanoma cell death
following [pIC]PEI treatment. MDA-5 is
a dsRNA helicase implicated in inter-
feron-mediated innate immune responses
(Kato et al., 2006). Yet the Soengas group
show that the [pIC]PEI complex can en-
gage MDA-5 and promote tumor cell
death even in highly immunosuppressed
mice. Recruitment of the small GTPase
Rab7 and lysosomal activity were also
identified by the authors as important for
persistent cycles of fusion events. Al-
though autophagy in innate immunity is
normally cytoprotective, the authors re-
vealed that components of the classic
autophagy pathway are required for con-
comitant induction of cell death in res-
ponse to [pIC]PEI treatment. As immune
tolerance is a defining characteristic of
melanoma tumors (Kirkwood et al., 2008),
these results could provide an alternative
to melanoma therapy.
Intriguingly, cell death reported following
[pIC]PEI treatment took place several hours
after initiation of autophagy. Among the
components required for efficient tumor
cell demise were NOXA and caspases,
which are bona fide cell death inducers.
The link between autophagy and cell death
wasfurthersubstantiatedbydemonstrating
MDA5-dependent activation of NOXA and
that [pIC]PEI-induced autophagy/cell death
of melanoma cells required both MDA5
and NOXA. A possible explanation for the
link between autophagy and cell-death
induction is provided by the sustained
waves of endosome generation/matura-
tion/resolution (Figure 1), which may lower
the threshold for activation of death
programs,althoughsupport for thishypoth-
esis, as well as the nature of the delayed
response, awaits further investigation.
The possible therapeutic significance of
these findings is illustrated by the use ofll 16, August 4, 2009 ª2009 Elsevier Inc. 83
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[pIC]PEI-mediated tumor cell death can be achieved via two pathways. First, [pIC]PEI uptake induces
multiple endosomal mobilization followed by release to cytosol and activation of autophagy. Multiple
sustained waves of endosome/autophagosome/lysosomal fusion events may cause depletion of vital
cellular components (that maintains threshold of viability), followed by cell death or sensitization of cells
to subsequent activation of cell-death machinery. Second, activation of MDA-5 links to NOXA expression
and caspase-dependent cell death, which can be facilitated by the first mechanism.Overall, two pathways
(possibly interlinked) potentiate melanoma cell death.a genetically engineered mouse mela-
noma model (Tyr::NRasQ61K/Ink4a/Arf/)
in addition to xenografts of melanoma
cells in both immune-competent and
-deficient mice. In all systems, [pIC]PEI
efficiently reduced melanoma tumor
burden with a corresponding decrease in
metastasis. The reduced sensitivity of
MDA-5-deficient transformed MEFs to
[pIC]PEI in the xenograft model compared
with MDA-5-expressing cells further
supports a central role for autophagy in
programmed death of these tumor cells.
These findings raise several questions:
among them is the selectivity of [pIC]PEI
toward melanoma, but not melanocytes
or fibroblasts. Understanding the basis
of such selectivity would not only signifi-
cantly contribute to understanding how
melanoma cells respond to various thera-84 Cancer Cell 16, August 4, 2009 ª2009 Elpies, but also indicate if normal cell types
could be inadvertently targeted. Another
question relates to the use of PEI. Naked
pIC was found to signal just transiently in
melanoma cells, likely as a result of its
degradation in the cytosol or negative
feedback that blunts antiviral responses
(Stetson and Medzhitov, 2006). As PEI
enhances delivery of nucleic acids to the
cytosol (Akinc, et al., 2005), it is plausible
that [pIC]PEI might escape the degradative
pathway, leading to sustained autophagy
and MDA-5 activation (Figure 1). Further
studies could determine the underlying
mechanism and perhaps identify other
compounds of similar or greater efficacy
and selectivity. Lastly, it is of equal impor-
tance to assess the potential for develop-
ment of resistance to this treatment. Also
of interest is to elucidate the regulation ofsevier Inc.endosomal dynamics and its putative
contribution to cell death, which are
largely unexplored and are relevant for
melanosome biogenesis and melanoma
biology.
Taken together, this work offers new
insight into the induction of endosome-
mediated autophagy as a means to pro-
mote melanoma cell death. It also sheds
light on the use of dsRNA as a therapeutic
strategy and the role of MDA5 and NOXA
in endosomal maturation linked to auto-
phagic death. Given the failure rate in
melanoma therapy and the fact that most
melanoma therapies have utilized rather
traditional approaches, this work offers
new thoughts on potential treatment of
this devastating cancer.
REFERENCES
Akinc, A., Thomas, M., Klibanov, A.M., and Langer,
R. (2005). J. Gene Med. 7, 657–663.
Eisenberg-Lerner, A., and Kimchi, A. (2009).
Apoptosis 14, 376–391.
Ivanov, V.N., Bhoumik, A., and Ronai, Z. (2003).
Oncogene 22, 3152–3161.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M.,
Yamanoto, M., Matsui, K., Uematsu, S., Jung, A.,
Kawai, T., Ishii, K.J., et al. (2006). Nature 441,
101–105.
Kirkwood, J.M., Tarhini, A.A., Panelli, M.C.,
Moschos, S.J., Zarour, H.M., Butterfield, L.H.,
and Gogas, H.J. (2008). J. Clin. Oncol. 26, 3445–
3455.
Levine, B., and Kroemer, G. (2008). Cell 132, 27–
42.
Maiuri, M.C., Zalckvar, E., Kimchi, A., and
Kroemer, G. (2007). Nat. Rev. Mol. Cell Biol. 8,
741–752.
Stetson, D.B., and Medzhitov, R. (2006). Immunity
25, 373–381.
Tormo, D., Che˛cin˜ska, A., Alonso-Curbelo, D.,
Pe´rez-Guijarro, E., Can˜o´n, E., Riveiro-Falkenbach,
E., Calvo, T.G., Larribere, L., Megı´as, D., Mulero,
F., et al. (2009). Cancer Cell 16, this issue, 103–114.
Turcotte, S., Chan, D.A., Sutphin, P.D., Hay, M.P.,
Denny, W.A., and Giaccia, A.J. (2008). Cancer Cell
14, 90–102.
